Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Lung cancer roundup

ASCO 2026: Highlights and analysis

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC